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Abstract
A novel clinical entity characterized by ST segment elevation in right precordial leads (V1 to V3),
incomplete or complete right bundle branch block, and susceptibility to ventricular
tachyarrhythmia and sudden cardiac death has been described by Brugada et al. in 1992. This disease
is now frequently called "Brugada syndrome" (BrS). The prevalence of BrS in the general population
is unknown. The suggested prevalence ranges from 5/1,000 (Caucasians) to 14/1,000 (Japanese).
Syncope, typically occurring at rest or during sleep (in individuals in their third or fourth decades
of life) is a common presentation of BrS. In some cases, tachycardia does not terminate
spontaneously and it may degenerate into ventricular fibrillation and lead to sudden death. Both
sporadic and familial cases have been reported and pedigree analysis suggests an autosomal
dominant pattern of inheritance. In approximately 20% of the cases BrS is caused by mutations in
the SCN5A gene on chromosome 3p21-23, encoding the cardiac sodium channel, a protein involved
in the control of myocardial excitability. Since the use of the implantable cardioverter defibrillator
(ICD) is the only therapeutic option of proven efficacy for primary and secondary prophylaxis of
cardiac arrest, the identification of high-risk subjects is one of the major goals in the clinical
decision-making process. Quinidine may be regarded as an adjunctive therapy for patients at higher
risk and may reduce the number of cases of ICD shock in patients with multiple recurrences.
Definition
Brugada syndrome (BrS; OMIM 601144), or "Idiopathic
ventricular fibrillation" as defined by some authors [1], is
an autosomal dominant form of cardiac arrhythmia, pre-
senting with a typical electrocardiographic (ECG) pattern
of ST segment elevation in leads V1 to V3, and incomplete
or complete right bundle branch block [2]. Syncope, typi-
cally occurring at rest or during sleep, is a common pres-
entation of BrS [3], and it is caused by fast polymorphic
ventricular tachycardia. In some cases, tachycardia does
not terminate spontaneously. It may degenerate into ven-
tricular fibrillation and lead to sudden death.
Epidemiology
The incomplete information concerning the genetic bases
of BrS prevents a prevalence assessment among the gen-
eral population. The current estimate is based upon ECG
surveys among healthy subjects. These studies have been
mostly done in the Asian population and only one has
been carried out among Caucasians. The suggested preva-
lence ranges from 5/1,000 (Caucasians) to 14/1,000 (Jap-
anese) [4-6]. The higher prevalence of the BrS ECG pattern
in far eastern countries has been recently confirmed in a
large clinical study [7] (see paragraph Genetic bases and
pathophysiology). In this region the disease is thought to
represent a frequent cause of sudden death among young
individuals and is named as: lai-tai, pokkuri, sudden
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unexplained death syndrome, sudden unexplained noc-
turnal death syndrome.
Clinical description
BrS manifests with syncope and cardiac arrest, typically
occurring in the third and fourth decade of life, and usu-
ally at rest or during sleep. In 1998 Brugada et al. pre-
sented data on 63 patients in whom, after a mean follow
up of 34 ± 32 months, 34% of previously symptomatic
(syncope and/or cardiac arrest) patients had recurrence,
while a first cardiac event occurred in 27% of the asymp-
tomatic individuals. These results called for an aggressive
therapeutic strategy in all patients with BrS and, since no
pharmacological treatment of proven efficacy was (and
still is) available, it led to implantable cardioverter defi-
brillator (ICD) implants in several young asymptomatic
individuals. However, a different picture is emerging from
more recent epidemiological surveys. In 2000, Priori et al.
showed an incidence of 16% for the recurrence of a car-
diac arrest in symptomatic patients, while none of the
asymptomatic individuals at enrolment had a cardiac
event after three years of follow up [8]. The low incidence
of events at follow up in the subgroup of patients who are
asymptomatic at diagnosis has been subsequently con-
firmed by several authors [7,9-12]. It is important to stress
the concept that this figure might be biased by the fact that
it is currently not known whether a Brugada-like ECG
always indicates the presence of the disease or whether it
is a non-specific finding in some cases.
ECG pattern
BrS is characterized by a typical ECG pattern of incom-
plete or complete right bundle branch block and ST seg-
ment elevation (≥ 2 mm) in leads V1 through V3 with a
"coved morphology". This pattern may be spontaneously
evident or induced by a provocative pharmacological test
with sodium channel blockers (Ajmaline or Flecainide).
The diagnostic criteria for BrS have been recently updated
and summarized in a consensus article [13]. According to
this document Brugada syndrome can be established in
the presence of:
1) ST-segment elevation (type 1, figure 1) in more than
one right precordial lead (V1 to V3), and one of the fol-
lowing: documented ventricular fibrillation; self terminat-
ing polymorphic ventricular tachycardia; a family history
of sudden cardiac death (<45 years); coved type ECGs in
family members; electrophysiological inducibility; syn-
cope. There should be no other factor(s) that can account
for the ECG abnormality.
2) Appearance of type 2 ST-segment elevation ("saddle-
back type") (figure 1) in more than one right precordial
lead upon challenge with a sodium channel blocker. A
drug-induced ST-segment elevation to a value >2 mm
should raise the possibility of Brugada syndrome when
one or more clinical criteria are present (see the case 1
above).
3) Appearance of type 3 ST segment elevation in more
than one lead under baseline conditions with conversion
to type 1 after challenge with a sodium channel blocker is
considered equivalent to case 1 above.
Genetic bases and pathophysiology
At the present time, only one BrS-related gene is known.
Mutations in the cardiac sodium channel gene, SCN5A,
on chromosome 3p21-23, were identified by Chen in
1998 [14]. Interestingly, BrS is not the only phenotype
linked to mutations in this gene. Known allelic disorders
are: the LQT3 variant of Long QT syndrome [15] (OMIM
603830), the progressive cardiac conduction defect
(PFHB, OMIM 113900) and the Sick sinus syndrome
(SSS1; OMIM 608567) [16-18]. In vitro expression of
mutant SCN5A proteins showed that BrS, PFHB and SSS1
are characterized by a loss of sodium channel function,
whereas in LQT3 there is an excess of sodium inward cur-
rent [14]. To add to the complexity of the SCN5A-related
phenotypes, overlapping syndromes have been also
described in association with some specific SCN5A muta-
tions that may cause the coexistence of LQT3 and BrS [19-
21] or LQT3, BrS and PFHB in the same individuals
[17,22].
Unfortunately,  SCN5A  mutations account for approxi-
mately 20% of BrS cases [23]. Only one additional locus
(on chromosome 3p22-25 [24]) has been identified by
linkage analysis in a single large family, but, despite
screening of several candidates in the region, the corre-
sponding gene has not been found.
A possible explanation of the race-specific differential
prevalence of the BrS phenotype has been suggested by
Bezzina et al. [25]. Resequencing of the SCN5A promoter
region allowed these authors to identify an Asian-specific
haplotype: a six single nucleotide polymorphism (SNP)
block not present among Caucasians, that is associated
with lower transcription activity of the gene. The haplo-
type has an impressively high frequency of 0.22 in the
Asian population and it is clinically associated with a
reduced intraventricular conduction velocity. Thus, a con-
stitutively reduced inward sodium current (INa) may be
present and favor the high rate of occurrence of the BrS
ECG pattern in far east countries.
Cardiac structural abnormalities in Brugada syndrome 
Genotype-phenotype relationship
In their initial report on eight patients, Brugada et al.
emphasized the lack of structural cardiac abnormalities
[2]. However, at that time other authors had alreadyOrphanet Journal of Rare Diseases 2006, 1:35 http://www.OJRD.com/content/1/1/35
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reported the typical V1-V3 ST segment elevation and right
bundle branch block in some patients with arrhyth-
mogenic right ventricular cardiomyopathy (ARVC; OMIM
107970) [26,27]., thus suggesting a possible overlap
between these clinical entities.
More consistent data on a causal relationship between
SCN5A mutations and structural abnormalities have been
reported thereafter. The initial anecdotal cases of dilated
cardiomyopathy (DCM) [28] and histological abnormali-
ties [29] in SCN5A mutation carriers have been recently
confirmed by systematic screening for this gene in DCM
probands. These studies identified five allelic variants co-
segregating with the phenotype [30,31]. Finally, Frustaci
et al. reported structural degeneration (fibrosis) and apop-
tosis during the analysis of myocardial biopsies of
patients with a clinical diagnosis of Brugada syndrome
and a SCN5A mutation [32]. Taken as a whole, these stud-
ies strongly suggest that at least some SCN5A mutations
manifest as both excitability and structural derangement.
On a clinical basis, this possibility should always be con-
sidered and it advocates the need of careful echo and
nuclear magnetic resonance (NMR) studies on all BrS
patients.
The role of molecular diagnosis in BrS
SCN5A  has a 6.048 Kb coding sequence spanning 28
exons. As of January 2006, approximately 160 SCN5A
mutations had been reported[33], and approximately
65% of them are associated with a BrS phenotype, but no
specific clustering within the coding region is demonstra-
ble. No hot spots have been reported.
As a result of this genetic heterogeneity, the screening for
known mutations is not feasible. Therefore, most of the
molecular analysis laboratories usually screen the SCN5A
coding region by performing single strand conforma-
tional polymorphism (SSCP) or denaturing high perform-
ance liquid chromatography (DHPLC), and DNA
sequencing.
ECG pattern in Brugada syndrome Figure 1
ECG pattern in Brugada syndrome. According to recent consensus document (ref 13), type 1 ST segment elevation either 
spontaneously present or induced with Ajmaline/Flecainide test is considered diagnostic. Type 1 and 2 may lead to suspicion 
but drug challenge is required for diagnosis. The ECGs in the right and left panels are from the same patient before (right panel, 
type 1) and after (left panel, type 1) endovenous administration of 1 mg/kg of Ajmaline during 10 minutes.
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Establishing a diagnosis of BrS in an asymptomatic indi-
vidual based on the ECG phenotype is a big responsibility
for the clinician, as it implies informing a young "healthy"
subject that they are at risk of sudden death and are at risk
of generating affected offspring.
Molecular genetics may free the cardiologist from the bur-
den of defining the diagnosis in difficult cases. This may
be particularly important in conditions such as BrS that
may present incomplete penetrance [34,35]. In this case,
the detection of a genetic defect within a family may rep-
resent the only tool for the identification of all those who
are at risk of cardiac events and transmitting the disease to
their offspring. This information has a direct impact on
clinical management. Obviously, the limited yield of
genetic testing in BrS does not allow diagnosis to be
excluded in negative patients.
Furthermore, with the exception of a tendency for a more
severe conduction delay among patients carrying a muta-
tion in SCN5A [36], clinical manifestations do not differ
between genotyped and not-genotyped patients, thus
making genotyping an inappropriate method for risk
stratification [23].
Differential diagnosis
ST segment elevation in leads V1-V3 may be found during
acute anterior myocardial infarction. In such instances,
angina pectoris and myocardial necrosis markers – creat-
ine kinase (CK), creatine phosphokinase-MB (CPK-MB),
Troponin I and lactate dehydrogenase (LDH) – are com-
mon findings and the differential diagnosis is easily estab-
lished. Furthermore, there are several other disorders in
which, although not constantly observed, ECG abnormal-
ities resembling BrS may develop: arrhythmogenic right
ventricular dysplasia/cardiomyopathy, Prinzmetal's vari-
ant angina, acute pericarditis/myocarditis, Friedreich's
ataxia, Duchenne muscular dystrophy, hypercalcemia/
vitamin D intoxication, hyperkalemia, acute pulmonary
thromboembolism, acute cholecystitis, transthoracic car-
dioversion, myotonic dystrophy type 1, Chagas disease,
hypothermia, vomiting. Obviously, all of the above men-
tioned disorders should be considered in patients with
suspected BrS.
Besides specific diseases, before BrS diagnosis can be defi-
nitely established, it is important to exclude drug-related
causes of BrS-like ECG patterns. All antiarrhythmic drugs
with a sodium channel blocking effect, especially class Ia
and Ic drugs, must be avoided (asymptomatic BrS patients
are often diagnosed incidentally after administration of
one of these compounds to treat supraventricular arrhyth-
mias). Other drugs reported to be potentially pro-arrhyth-
mic in Brugada syndrome patients are:
￿ Local anesthetics (non antiarrhythmic): bupivacaine
[37];
￿ Cocaine[38];
￿ Alpha adrenergic agonists: methoxamine, noradrenaline
[39];
￿ Beta-blockers: propranolol [39];
￿ Potassium channel activators: pinacidil [40];
￿ Parasympathetic agonists: acetylcholine [41];
￿ Ergot alkaloids: ergonovine [41];
￿ Tricyclic antidepressants [42];
￿ Opioid analgesics: propoxyphene [43];
￿ Lithium [44];
￿ First-generation antihistamines: dimenhydrinate [45];
￿ Propofol [46].
Clinical management and risk stratification
Being affected by a genetically determined disease, BrS
patients are exposed to a life-long risk of events, but the
disease is usually characterized by very long (years) inter-
vals of complete well-being between the cardiac events.
Therefore, the implant of an ICD may remarkably impair
quality of life and it is of utmost importance to precisely
identify the subgroup of individuals in whom this aggres-
sive therapeutic approach is mandatory because of their
high-risk of cardiac events.
Treatment guidelines for Brugada syndrome clearly
emphasize that patients who have already experienced a
cardiac arrest should receive an ICD [47]. However, these
patients are in the minority, since most BrS patients are
either asymptomatic or are referred with one or few syn-
copal spells in their clinical history. Risk stratification in
these latter subgroups requires careful evaluation of the
clinical presentation. Observational studies [23,48]. on
the natural history of BrS in large cohorts concordantly
suggest that patients with a history of syncope plus a spon-
taneously abnormal ECG (i.e. independent of the provoc-
ative test with intravenous sodium channel blockers) have
an approximately 6-fold higher risk of cardiac events (syn-
cope and cardiac arrest) as compared with asymptomatic
patients and patients in whom the diagnosis is established
only after a provocative test. The presence of only sponta-
neous ST segment elevation was associated with a moder-
ate risk of life-threatening events (Hazard Ratio 2.1) [49],Orphanet Journal of Rare Diseases 2006, 1:35 http://www.OJRD.com/content/1/1/35
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while a history of syncope alone was not an independent
predictor of outcome. These patients, as well as the silent
gene carriers, belong to a low risk group. Although rare
instances of life-threatening events may occur among this
latter category, the most effective strategies for their iden-
tification remain to be established and the wide-spread
use of ICD is not indicated, since device-related complica-
tions outweigh the benefits.
The role of programmed electrical stimulation (PES) as a
risk stratification tool in Brugada syndrome is still a mat-
ter of debate. While some authors support it [13,50], oth-
ers have provided experimental evidence suggesting a
poor predictive value and low reproducibility [23,51] Sev-
eral factors have been advocated to explain this discrep-
ancy [52] and two prospective studies (that are likely to
provide a definitive answer to this issue) are now ongoing,
one in the USA and one in Italy.
Pharmacological therapy
Quinidine, a non-specific blocker of cardiac transient out-
ward current (Ito) has been proposed as a gene-specific
therapy for BrS. This proposal is based on the idea that the
loss of sodium inward current in BrS, tilts the balance
between outward and inward currents, with an abnormal
shift in the outward direction at the end of phase 1 of the
action potential. Since transmural distribution of tran-
sient inward current is not uniform, this condition creates
a dispersion of repolarization and arrhythmogenic sub-
strate [53]. By blocking repolarizing currents, and specifi-
cally Ito, which is active during the initial phases of the
action potential, quinidine could restore the equilibrium
[54]. Based on this appealing theory, some authors have
attempted a gene-specific therapeutic approach for BrS.
The available clinical data show that quinidine prevents
arrhythmia inducibility at PES in up to 76% of BrS
patients [55-57] and suggest a positive long-term effect in
preventing the occurrence of spontaneous arrhythmias
[57]. Although no final proof of effectiveness is available,
quinidine may be regarded as an adjunctive therapy for
patients at higher risk and may reduce the number of cases
of ICD shock in patients with multiple recurrences.
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